Siemens and Exyte join forces to deliver integrated solutions for fast-track construction of smart biotech facilities
Covid-19 poses major challenges for developing and mass-producing vaccines and medicines in existing production facilities
Siemens and Exyte join forces to offer end-to-end solutions for the biopharmaceutical industry by combining the digitalization expertise of Siemens with the innovation boost from Exyte.
Model of a biopharmaceutical facility consisting of pre-configured ExyCell® modules and an integrated power supply by Siemens.
Copyright: Exyte
Against the background of the current challenges associated with the Covid-19 pandemic, pharmaceutical companies are facing challenges in developing and mass-producing new vaccines and medicines in existing production facilities. Siemens and Exyte are committed to tackle those challenges. Together, they offer standardized, turnkey solutions compliant with cGMP (current Good Manufacturing Practice) and GAMP (Good Automated Manufacturing Practice) to biotechnology manufacturers as well as cell and gene therapy manufacturers.
Currently, the first buildings with Siemens’ technology and ExyCell modules are being designed for cell and gene therapy manufacturing and biologicals production in China and Europe.
“We are excited to collaborate with Exyte to provide pre-fabricated, modular biotechnology solutions with our technology already embedded. As a market leader for the pharmaceutical industry, we offer know-how for process automation with our Simatic PCS 7 and WinCC automation platforms, as well as power supply and fire protection for modular cleanrooms,” said Eckard Eberle, CEO Siemens Process Automation.
Luca Mussati, Vice President Pharmaceuticals & Biotechnology at Exyte states: “Our partnership with Siemens enables us to pre-integrate Siemens’ technology into ExyCell modules, thus offering clients end-to-end solutions for their facilities. Our collaboration allows our clients to reap the benefits of industry 4.0 without the necessity of engineering them from scratch each time, thus saving them time and money. ExyCell modules are suitable for new buildings as well as for the retrofit of existing buildings, and can be provided either in standard, off-the-shelf plant configurations, or modules that can be combined to meet specific customer requirements.”
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
Last viewed contents
Groundbreaking technology can turn cancer cells back into normal cells - Research findings have been transferred to the start-up biotech company BioRevert
ZELTWANGER Leaktesting & Automation GmbH - Dusslingen, Germany
Merck Opens New Life Science Center for Scientific Collaboration
Category:Oxidoreductases
Helping certain breast cancer patients with a 3 in 1 molecule
List_of_subjects_in_Gray's_Anatomy:_IV._Myology
Dens_invaginatus